Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057681 | 0.80 | DRD2 (0.63) | DRD2HTR2CGRM2CHRM2HTR1A | |
| SCHEMBL28818474 | 0.80 | DRD2 (0.59) | DRD2HTR2CGRM2CHRM4DRD4 | |
| SCHEMBL10476060 | 0.78 | CTSS (0.46) | — | |
| SCHEMBL24951042 | 0.75 | DRD2 (0.64) | DRD2HTR2CGRM2CHRM2HTR1A | |
| SCHEMBL1065758 | 0.75 | HTR2C (0.77) | DRD2HTR2CGRM2HTR1AHTR2B | |
| SCHEMBL21856317 | 0.75 | IDH2 (0.43) | — | |
| SCHEMBL6926283 | 0.75 | DRD2 (0.72) | DRD2HTR2CGRM2CHRM2HTR1A | |
| SCHEMBL20851092 | 0.75 | DRD2 (0.63) | DRD2HTR2CGRM2CHRM2HTR1A | |
| SCHEMBL1761033 | 0.75 | DRD2 (0.56) | DRD2HTR2CGRM2CHRM4DRD4 | |
| SCHEMBL21810792 | 0.75 | DRD2 (0.53) | DRD2HTR2CGRM2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | DRD2 462/4885HTR2C 1184/4885GRM2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.